News & Events

All the latest news and events from PhoreMost

PhoreMost promotes Dr Neil Torbett to Chief Executive Officer
1st March 2022

PhoreMost promotes Dr Neil Torbett to Chief Executive Officer

Cambridge, UK, 01 March 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced the promotion of Dr Neil Torbett to Chief Executive Officer, with immediate effect. Dr Torbett was previously the Company’s Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board. Dr Torbett joined PhoreM …

PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement
8th September 2020

PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement

Drug Discovery World feature article: ‘Target discovery and drug development – what comes after CRISPR?’
30th April 2020

Drug Discovery World feature article: ‘Target discovery and drug development – what comes after CRISPR?’

PhoreMost strengthens leadership team with two key appointments
3rd February 2020

PhoreMost strengthens leadership team with two key appointments

PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical
21st January 2020

PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration
7th January 2020

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development
4th November 2019

PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development

No events currently available